XML 41 R30.htm IDEA: XBRL DOCUMENT v3.26.1
Entity Wide Disclosures (Tables)
3 Months Ended
Mar. 31, 2026
Entity Wide Disclosures [Abstract]  
Summary of Revenue by Major Source
The following table disaggregates the Company’s revenue by major source (in thousands):
Three Months Ended
March 31,
20262025
Therapeutic Area
Metabolic$237,558 $148,015 
Oncology201,239 170,476 
Other93,318 95,836 
Central Nervous System80,207 54,901 
Cardiology56,261 58,279 
AVAI38,021 31,063 
Total revenue$706,604 $558,570 
Schedule of Segment Reporting Information, by Segment
Information about the one reportable segment, significant segment expenses and a reconciliation to condensed consolidated net income is as follows (in thousands):
Three Months Ended
March 31,
20262025
Revenue, net$706,604 $558,570 
Operating expenses:
Direct service costs, excluding depreciation and amortization - Employee compensation164,603 143,927 
Direct service costs, excluding depreciation and amortization - Other segment items (a)33,671 33,889 
Reimbursed out-of-pocket expenses312,004 202,404 
Total direct costs510,278 380,220 
Selling, general and administrative47,917 57,897 
Depreciation6,751 6,694 
Amortization155 236 
Total operating expenses565,101 445,047 
Income from operations141,503 113,523 
Other income, net:
Miscellaneous income (expense), net971 (1,816)
Interest income, net5,117 6,463 
Total other income, net6,088 4,647 
Income before income taxes147,591 118,170 
Income tax provision23,721 3,575 
Segment net income$123,870 $114,595 
Reconciliation of profit or loss
Adjustments and reconciling items— — 
Condensed consolidated net income$123,870 $114,595 
(a) Direct service costs, excluding depreciation and amortization - Other segment items includes costs related to inventory, leases, project subcontractors and other direct service costs.